£87 k during 2002–2005. Using RCT data rather than GPRD data for event probabilities, the mean cost was £8 k with the VIGOR RCT and £10 k with the CLASS RCT. CONCLUSIONS: The published cost-effectiveness analyses of coxibs lacked external validity and did not represent patients in actual clinical practice. External validity should be an explicit requirement in cost-effectiveness analyses.

**PODIUM SESSION I: MENTAL HEALTH I (ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN EUROPE)**

**HOW MUCH SHOULD WE BE PREPARED TO PAY FOR PSYCHOSOCIAL INTERVENTIONS FOR PATIENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)? Schlander M1, Schwarz O1, Hakkart-van Roijen L2, Jensen PS1, Persson U3, Santosh PJ4, Trott GE5, MTA Cooperative Group 6, Schlander M1, Schwarz O1, Hakkaart-van Roijen L2, Jensen PS3, Trott GE6, MTA Cooperative Group 7**

1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany; 2Erasmus MC, Rotterdam, The Netherlands; 3Columbia University, New York, NY, USA; 4The Swedish Institute for Health Economics, IHE, Lund, Sweden; 5Institute of Child Health—Great Ormond Street Hospital, London, UK; 6University of Wuerzburg, Aschaffenburg, Germany; 7National Institute of Mental Health, Bethesda, MD, USA

**OBJECTIVES:** Notwithstanding evidence showing its clinical effectiveness, little if any data have supported the cost-effectiveness of psychosocial interventions for patients with ADHD. The NIMH-initiated MTA study was designed to maximize clinical effectiveness of psychosocial interventions in children with ADHD. We use patient-level data from this study to estimate the maximum allowable cost of better-targeted behavioral interventions that would still meet currently used benchmarks for cost-effectiveness in Europe, assuming they replicate clinical effectiveness as reported in the MTA study. **METHODS:** A total of 579 children age 7–9.9 years with ADHD (DSM-IV) were randomly assigned medication management (MedMgt), intense behavioral treatment (Beh), both combined (Comb), or community care (CC). All MTA treatment strategies were clinically effective. Costing from a societal perspective for Germany, The Netherlands, Sweden, and UK excluded the research component of the study. Treatment response was defined as normalization of core symptoms after 14 months. QALYs were estimated using utility weights derived from UK expert and parent-proxy-ratings. Comb was most effective, and Med dominated Beh economically. Using this data, we estimated the maximum allowable cost (MAC) of Comb versus Med, quantifying the uncertainty by means of non-parametric bootstrapping. **RESULTS:** MACs and their 95% confidence intervals for Comb versus Med were determined (a) for ADHD, and for subgroups with (b) “pure” ADHD (without comorbidity, n = 184) and (c) hyperkinetic disorder (HKD, with or without conduct disorder, n = 145), assuming (1) Comb meeting an ICER threshold (when added to MedMgt) of (1) £50,000 or (2) £100,000 per QALY. MACs for UK were (1) £2943 (£2569–£3310) and (2) £3328 (£2612–£4043). Estimates for Germany and The Netherlands were lower, whereas Swedish estimates were broadly in line with UK data. **CONCLUSIONS:** Despite some limitations, which will be discussed, these estimates may assist designing clinical studies to support acceptable cost-effectiveness of psychosocial treatment strategies for ADHD.

**THE SUSTAINED DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER FROM CHILDHOOD TO ADULTHOOD: A MEDICAID STUDY**

Chen H, Sudharshan L

University of Houston, Houston, TX, USA

**OBJECTIVES:** To determine the percentage of patients who had a continued diagnosis of attention-deficit hyperactivity disorder (ADHD) from childhood to adulthood in real practice and to examine the association between the sustained diagnosis of ADHD, other mental health comorbidities and the exposure to psychotropic medications. **METHODS:** A retrospective longitudinal analysis was conducted using the 1995 to 2001 Medicaid claims data. The study cohort were patients 4–17 years of age who received a diagnosis of ADHD in the year 1995. These patients were then followed through 2001 to determine the percentage that retained the diagnosis of ADHD. Multivariate regression analysis was employed to assess the association between sustained ADHD diagnosis, other mental health comorbidities (conduct disorder, oppositional defiant disorder, mood disorders, anxiety disorder and substance abuse disorder) and the exposure to psychotropic medications (stimulants, antidepressants, antipsychotics, antianxietytics, anticonvulsants). **RESULTS:** A total of 18,131 patients were identified with a diagnosis of ADHD in 1995 and had continuous Medicaid eligibility during the 7 year follow-up period. Out of those only 10,746 (57.77%) retained a diagnosis of ADHD in the first year follow-up and merely 1530 (8.43%) retained the diagnosis of ADHD in 2001. The length of retaining ADHD diagnosis is positively associated with the early exposure to stimulants and having mental health comorbidities such as mood disorders, anxiety disorder, conduct disorder and oppositional defiant disorder. **CONCLUSIONS:** The result is in confirmation with previous prospective studies which indicated that ADHD shows a remission with maturation. However, the proportion of patients retaining ADHD diagnosis in real practice is 60% to 80% lower than the findings of those prospective studies, which suggests a significant gap between knowledge advancement and practice. Further study is needed to clarify the relationship between psychopharmacotherapy and sustained diagnosis of ADHD from childhood to adulthood.

**COST-EFFECTIVENESS OF LONG-ACTING METHYLPHENIDATE FOR TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS IN FINLAND: AN EVALUATION BASED UPON A RANDOMIZED CLINICAL TRIAL (RCT)**

Schlander M1, Hjelmgren J2

1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany; 2Janssen-Cilag AB, Sollentuna, Sweden

**OBJECTIVES:** To evaluate the cost-effectiveness of methylphenidate (MPH)-OROS, a long-acting formulation given once daily (o.a.d.), compared to short-acting MPH (immediate-release, IR), which requires twice (b.i.d.) or thrice (t.i.d.) daily administration schedules, from a payer’s perspective in Finland. **METHODS:** Health care resource utilization was estimated based on the Canadian ADHD RCT by Steele et al. (2006), comparing MPH-OROS (average dose at study end, 37.8 mg/d; n = 70) with usual care using MPH-IR (n = 73; hereof, 61% t.i.d., 34.6 mg/d; 39%, b.i.d., 31.4 mg/d) in an open-label ‘pragmatic’ parallel-group design over eight weeks. For costing, these data were combined with Finnish unit costs. Effectiveness was defined as intent-to-treat remission rates as determined by parent ratings (primary study endpoint: 18-item SNAP-IV scale). For an estimation of